Review
Copyright ©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Mar 15, 2025; 17(3): 100739
Published online Mar 15, 2025. doi: 10.4251/wjgo.v17.i3.100739
Helicobacter pylori-related serum indicators: Cutting-edge advances to enhance the efficacy of gastric cancer screening
Hao-Tian Sun
Hao-Tian Sun, Cancer Institute, University College London, London WC1E 6BT, United Kingdom
Author contributions: Sun HT designed the overall concept and outline of the manuscript, and wrote and edited the manuscript.
Conflict-of-interest statement: The author has no conflicts of interest to declare.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Hao-Tian Sun, Cancer Institute, University College London, Gower Street, London WC1E 6BT, United Kingdom. heaven202202@163.com
Received: August 30, 2024
Revised: December 8, 2024
Accepted: January 3, 2025
Published online: March 15, 2025
Processing time: 169 Days and 19.9 Hours
Core Tip

Core Tip: Traditional serum tumor markers exhibit low diagnostic efficacy. Although gastrin and pepsin reflect the current state of the stomach, their clinical application remains impractical. New molecular biomarkers, such as noncoding genomes, have potential utility in diagnosing and screening for gastric cancer (GC); however, further validation is required. Serum anti-Helicobacter pylori antibodies have been used in various combined examination methods for GC screening, and the relationship between specific antibodies to virulence factors and GC risk has been thoroughly researched. The application of multiple serological detection and prediction models has expanded the pool of candidate biomarkers for GC screening.